We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study
Read MoreHide Full Article
AstraZeneca (AZN - Free Report) has announced positive results from the phase III CAPItello-281 study, which evaluated a combination regimen involving its ATK inhibitor Truqap (capivasertib) in certain patients with prostate cancer.
The CAPItello-281 study evaluated the combination of Truqap, J&J’s (JNJ - Free Report) Zytiga (abiraterone) and androgen deprivation therapy (ADT) in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC).
Results from the study showed that patients treated with this combination achieved a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) when compared to those patients who only received standard of care (SoC) therapy, which is JNJ’s Zytiga plus ADT.
Though data for the key secondary endpoint of overall survival (OS) were not mature at the time, management claimed that the study showed an early trend toward OS improvement in patients treated with the Truqap combination. AstraZeneca intends to continue the study to assess the OS endpoint.
Per AstraZeneca, the above results are the first to show that adding an ATK inhibitor to SoC can benefit mHSPC patients with tumor PTEN deficiency, an aggressive form of prostate cancer with a poor prognosis. Management claims that about 200,000 patients are diagnosed with mHSPC, out of which nearly a quarter have PTEN-deficient tumors.
AZN Stock Performance
Year to date, AstraZeneca’s shares have lost 1.4% against the industry’s 5.7% growth.
Image Source: Zacks Investment Research
Recent Developments With AstraZeneca’s Truqap
Truqap has already approved by the FDA in combination with Faslodex to treat adult patients with advanced HR-positive breast cancer since last year. This combination received approval in the EU earlier this June to treat adult patients with advanced ER-positive breast cancer.
The above results are likely to provide relief to investors after a combination therapy involving Truqap missed a late-stage study goal in certain breast cancer patients. Earlier in June, AstraZeneca announced results from the CAPItello-290 study, which evaluated the combination of Truqap and paclitaxel for the first-line treatment of patients with locally advanced (inoperable) or metastatic triple-negative breast cancer. Data from the study showed that treatment with this combination failed to achieve one of the dual primary endpoints of OS.
Apart from the above studies, AZN is also evaluating Truqap in two separate late-stage studies – one in breast cancer and another in prostate cancer – in combination with established treatments.
AZN’s Zacks Rank
AstraZeneca currently carries a Zacks Rank #3 (Hold).
In the past 60 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from 58 cents to 8 cents. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.13 to $1.88. Year to date, shares of Castle Biosciences have surged 38.1%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 56 cents to 35 cents. Year to date, shares of CytomX Therapeutics have lost 42.6%.
CytomX Therapeutics’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 115.70%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study
AstraZeneca (AZN - Free Report) has announced positive results from the phase III CAPItello-281 study, which evaluated a combination regimen involving its ATK inhibitor Truqap (capivasertib) in certain patients with prostate cancer.
The CAPItello-281 study evaluated the combination of Truqap, J&J’s (JNJ - Free Report) Zytiga (abiraterone) and androgen deprivation therapy (ADT) in patients with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC).
Results from the study showed that patients treated with this combination achieved a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) when compared to those patients who only received standard of care (SoC) therapy, which is JNJ’s Zytiga plus ADT.
Though data for the key secondary endpoint of overall survival (OS) were not mature at the time, management claimed that the study showed an early trend toward OS improvement in patients treated with the Truqap combination. AstraZeneca intends to continue the study to assess the OS endpoint.
Per AstraZeneca, the above results are the first to show that adding an ATK inhibitor to SoC can benefit mHSPC patients with tumor PTEN deficiency, an aggressive form of prostate cancer with a poor prognosis. Management claims that about 200,000 patients are diagnosed with mHSPC, out of which nearly a quarter have PTEN-deficient tumors.
AZN Stock Performance
Year to date, AstraZeneca’s shares have lost 1.4% against the industry’s 5.7% growth.
Image Source: Zacks Investment Research
Recent Developments With AstraZeneca’s Truqap
Truqap has already approved by the FDA in combination with Faslodex to treat adult patients with advanced HR-positive breast cancer since last year. This combination received approval in the EU earlier this June to treat adult patients with advanced ER-positive breast cancer.
The above results are likely to provide relief to investors after a combination therapy involving Truqap missed a late-stage study goal in certain breast cancer patients. Earlier in June, AstraZeneca announced results from the CAPItello-290 study, which evaluated the combination of Truqap and paclitaxel for the first-line treatment of patients with locally advanced (inoperable) or metastatic triple-negative breast cancer. Data from the study showed that treatment with this combination failed to achieve one of the dual primary endpoints of OS.
Apart from the above studies, AZN is also evaluating Truqap in two separate late-stage studies – one in breast cancer and another in prostate cancer – in combination with established treatments.
AZN’s Zacks Rank
AstraZeneca currently carries a Zacks Rank #3 (Hold).
AstraZeneca PLC Price
AstraZeneca PLC price | AstraZeneca PLC Quote
Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are Castle Biosciences (CSTL - Free Report) and CytomX Therapeutics (CTMX - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Castle Biosciences’ 2024 loss per share have narrowed from 58 cents to 8 cents. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.13 to $1.88. Year to date, shares of Castle Biosciences have surged 38.1%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 56 cents to 35 cents. Year to date, shares of CytomX Therapeutics have lost 42.6%.
CytomX Therapeutics’ earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 115.70%.